In addition, inhibition of ACE2 enhances inflammation in the context of metabolic disease, while activation of ACE2 suppresses inflammation, suggesting that ACE2 activators may ameliorate the pro-inflammatory action of SARS-CoV-2 S protein (27). Here, PROS1 is linked to metabolic disease.